StockData
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. (MRKR) stock

MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/30
$0.87−0.03 (-3.33%)

Close on Nov 13, 2026Market cap $14.51MP/E –Yield –

Marker Therapeutics cash

Cash and short-term investments held at the end of each period.

Marker Therapeutics's cash was $11.33M at Jun 30, 2026. For fiscal 2025 it was $16.07M, down 16.3% from the year before. Over ten years it grew 9.3% a year on average. The highest annual figure on record is $61.75M in fiscal 2018.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$16.07M-16.3%
FY2024Dec 31, 2024$19.19M+27.0%
FY2023Dec 31, 2023$15.11M+28.3%
FY2022Dec 31, 2022$11.78M-72.9%
FY2021Dec 31, 2021$43.50M+103.7%
FY2020Dec 31, 2020$21.35M-51.4%
FY2019Dec 31, 2019$43.90M-28.9%
FY2018Dec 31, 2018$61.75M+1103.8%
FY2017Dec 31, 2017$5.13M-34.7%
FY2016Dec 31, 2016$7.85M+19.4%
FY2015Dec 31, 2015$6.58M+4533.2%
FY2014Dec 31, 2014$141.94K+192.1%
FY2013Dec 31, 2013$48.59K+43.6%
FY2012Dec 31, 2012$33.84K-86.5%
FY2011Dec 31, 2011$250.23K+964.1%
FY2010Dec 31, 2010$23.52K-83.4%
FY2009Dec 31, 2009$141.43K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$11.33M-4.1%
Q1 FY2026Mar 31, 2026$14.92M+8.9%
Q4 FY2025Dec 31, 2025$16.07M-16.3%
Q3 FY2025Sep 30, 2025$17.59M+95.5%
Q2 FY2025Jun 30, 2025$11.81M+51.5%
Q1 FY2025Mar 31, 2025$13.69M+20.9%
Q4 FY2024Dec 31, 2024$19.19M+27.0%
Q3 FY2024Sep 30, 2024$9.00M-48.5%
Q2 FY2024Jun 30, 2024$7.80M-57.0%
Q1 FY2024Mar 31, 2024$11.32M+76.9%
Q4 FY2023Dec 31, 2023$15.11M+28.3%
Q3 FY2023Sep 30, 2023$17.47M-3.3%
Q2 FY2023Jun 30, 2023$18.12M-29.8%
Q1 FY2023Mar 31, 2023$6.40M-77.8%
Q4 FY2022Dec 31, 2022$11.78M-72.9%
Q3 FY2022Sep 30, 2022$18.08M-62.9%
Q2 FY2022Jun 30, 2022$25.82M-54.9%
Q1 FY2022Mar 31, 2022$28.82M-55.3%
Q4 FY2021Dec 31, 2021$43.50M+103.7%
Q3 FY2021Sep 30, 2021$48.71M+80.7%
Q2 FY2021Jun 30, 2021$57.22M+78.1%
Q1 FY2021Mar 31, 2021$64.51M+60.2%
Q4 FY2020Dec 31, 2020$21.35M-51.4%
Q3 FY2020Sep 30, 2020$26.96M-44.4%
Q2 FY2020Jun 30, 2020$32.12M-39.9%
Q1 FY2020Mar 31, 2020$40.26M-30.2%
Q4 FY2019Dec 31, 2019$43.90M-28.9%
Q3 FY2019Sep 30, 2019$48.48M+522.9%
Q2 FY2019Jun 30, 2019$53.44M+1808.0%
Q1 FY2019Mar 31, 2019$57.71M+1025.0%
Q4 FY2018Dec 31, 2018$61.75M+711.6%
Q2 FY2018Jun 30, 2018$7.78M-21.9%
Q1 FY2018Mar 31, 2018$2.80M-52.7%
Q4 FY2017Dec 31, 2017$5.13M-34.7%
Q3 FY2017Sep 30, 2017$7.61M-20.6%
Q2 FY2017Jun 30, 2017$9.96M+164.4%
Q1 FY2017Mar 31, 2017$5.93M–
Q4 FY2016Dec 31, 2016$7.85M–
Q3 FY2016Sep 30, 2016$9.59M–
Q2 FY2016Jun 30, 2016$3.77M–

More Marker Therapeutics figures

See a number that looks wrong?